625 related articles for article (PubMed ID: 29650132)
61. [Benefit of bladder and upper urinary tract urothelial tumors lymph node dissection: review from the Bladder Cancer Committee of the French National Association of Urology ("CC-AFU Vessie")].
Larré S; Quintens H; Houéde N; Compérat E; Roy C; Pignot G; Rouprêt M; Neuzillet Y; Wallerand H; Soulié M; Pfister C
Prog Urol; 2012 Jun; 22(7):380-7. PubMed ID: 22657257
[TBL] [Abstract][Full Text] [Related]
62. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract.
Ku JH; Choi WS; Kwak C; Kim HH
Urol Oncol; 2011; 29(4):383-7. PubMed ID: 19556154
[TBL] [Abstract][Full Text] [Related]
63. [Clinical and pathologic characteristics of small cell neuroendocrine carcinoma of urinary tract].
Guo AT; Chen W; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):747-51. PubMed ID: 23302335
[TBL] [Abstract][Full Text] [Related]
64. Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Lu DD; Boorjian SA; Raman JD
Urol Oncol; 2017 Mar; 35(3):113.e1-113.e7. PubMed ID: 27884539
[TBL] [Abstract][Full Text] [Related]
65. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
Calleris G; Rouprêt M; Seisen T; Bendjeddou L; Chevallier T; Masson-Lecomte A; Thibault C; Neuzillet Y; Audenet F; Xylinas E; Houédé N
World J Urol; 2023 Dec; 41(12):3413-3420. PubMed ID: 37698632
[TBL] [Abstract][Full Text] [Related]
66. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Leow JJ; Martin-Doyle W; Fay AP; Choueiri TK; Chang SL; Bellmunt J
Eur Urol; 2014 Sep; 66(3):529-41. PubMed ID: 24680361
[TBL] [Abstract][Full Text] [Related]
67. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
68. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
69. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
[TBL] [Abstract][Full Text] [Related]
70. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
[TBL] [Abstract][Full Text] [Related]
71. [Transitional cell carcinoma of the upper urinary tract following total cystectomy for bladder cancer].
Hayashi Y; Tawada T; Ando Y
Hinyokika Kiyo; 1992 Sep; 38(9):1015-8; discussion 1018-9. PubMed ID: 1414752
[TBL] [Abstract][Full Text] [Related]
72. Contemporary update on neoadjuvant therapy for bladder cancer.
Nguyen DP; Thalmann GN
Nat Rev Urol; 2017 Jun; 14(6):348-358. PubMed ID: 28290459
[TBL] [Abstract][Full Text] [Related]
73. Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database.
Kapadia AA; Martinez Acevedo A; Liu JJ; Garzotto M; Conlin M; Amling C; Kopp RP
J Urol; 2018 Sep; 200(3):535-540. PubMed ID: 29551404
[TBL] [Abstract][Full Text] [Related]
74. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
75. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
[TBL] [Abstract][Full Text] [Related]
76. [Adjuvant polychemotherapy after radical cystectomy of metastatic bladder cancer].
Stöckle M
Urologe A; 1994 Nov; 33(6):568-75. PubMed ID: 7817458
[TBL] [Abstract][Full Text] [Related]
77. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis.
Kim DK; Lee JY; Kim JW; Hah YS; Cho KS
Crit Rev Oncol Hematol; 2019 Mar; 135():59-65. PubMed ID: 30819447
[TBL] [Abstract][Full Text] [Related]
78. Perioperative chemotherapy for upper tract urothelial cancer.
Alva AS; Matin SF; Lerner SP; Siefker-Radtke AO
Nat Rev Urol; 2012 Apr; 9(5):266-73. PubMed ID: 22487872
[TBL] [Abstract][Full Text] [Related]
79. Radical cystectomy in the elderly: Comparison of survival between younger and older patients.
Clark PE; Stein JP; Groshen SG; Cai J; Miranda G; Lieskovsky G; Skinner DG
Cancer; 2005 Feb; 103(3):546-52. PubMed ID: 15630702
[TBL] [Abstract][Full Text] [Related]
80. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder.
Svatek RS; Shariat SF; Lasky RE; Skinner EC; Novara G; Lerner SP; Fradet Y; Bastian PJ; Kassouf W; Karakiewicz PI; Fritsche HM; Müller SC; Izawa JI; Ficarra V; Sagalowsky AI; Schoenberg MP; Siefker-Radtke AO; Millikan RE; Dinney CP
Clin Cancer Res; 2010 Sep; 16(17):4461-7. PubMed ID: 20651056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
